Content about Sanofi

CHATTANOOGA, Tenn. — Chattem on Tuesday introduced Cortizone 10 Poison Ivy Relief Pads featuring a new anti-itch format trademarked the Snapplicator. 

"The innovative packaging is the first of its kind for poison ivy relief," stated Liz Roques, assistant brand manager at Chattem. "The individual Snapplicators include a single treatment so consumers don't have to touch the affected area."

CAMBRIDGE, Mass. — Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.

Genzyme, a division of French drug maker Sanofi, announced results of an extension study of the drug Lemtrada (alemtuzumab). The study was a follow-up to two other late-stage clinical studies of the drug, finding that relapse rates and sustained accumulation of disability remained low among patients who had previously received the drug.

The generic drug tidal wave became a tsunami in 2012, with some of the world's top-selling pharmaceuticals swamped by generic competition, and health plan payers scrambling to reap billions of dollars in financial savings.

OMAHA, Neb. — Sergeant's Pet Care Products has launched a generic version of a commonly used spray for killing fleas and ticks in dogs and cats, the company said Tuesday.

Sergeant's announced the launch of Pronyl, a version of Sanofi's Frontline. Pronyl uses the same active ingredient, Fipronil, but also uses what the company calls Bag-on-Valve technology that allows a continuous and quiet spray from any angle.

COCOA, Fla. — Sun & Skin Care Research announced on Monday that it has completed the acquisition of the Bull Frog sunscreen brand from Chattem, a division of Sanofi U.S.

PARIS — During a quarterly conference call Thursday, Sanofi president of global operations Hanspeter Spek noted that Sanofi's consumer arm Chattem will be relaunching the heartburn remedy Rolaids.

"We plan to relaunch the product, which has been absent of the American markets for production problems on the side of J&J," he told analysts. "We intend to launch the product by the end of 2013, which will further accelerate the performance of Chattem in the United States."

CAMBRIDGE, Mass. — The Food and Drug Administration has accepted a regulatory approval application from Genzyme for an experimental treatment for multiple sclerosis, the company said Monday.

Genzyme, a division of French drug maker Sanofi, said the FDA accepted its application seeking approval for Lemtrada (alemtuzumab) for relapsing MS. The company expects the agency to decide whether to approve the drug in the second half of this year.

PARIS — Sanofi on Monday announced that its U.S. Consumer Healthcare Division Chattem, completed the acquisition of the worldwide rights to the Rolaids brand from McNeil Consumer Healthcare for an undisclosed amount.

SAN DIEGO — Consumers who purchased Chattem’s ACT Total Care Anticavity Fluoride Mouthwash between Jan. 1, 2009, and June 30, 2010, may be entitled to a cash refund from a class action settlement, according to a statement issued by the manufacturer.

In 2011 and 2012, the steady surge of blockbuster pharmaceuticals falling off the patent cliff became a stampede. An astonishing number of big-selling drugs that had established and sustained branded drug makers’ profits for years fell victim to the expiration of their patent lives and market exclusivity, roiling the pharmaceutical marketplace and redefining the pricing model for many of the most widely prescribed classes of medicines.


SWIFTWATER, Pa. — Sanofi Pasteur announced Monday the presentation of three clinical trials of an experimental influenza vaccine.